Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $42.2 million.

  • Zenas BioPharma's Shares Outstanding (Weighted Average) rose 44768.78% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 44768.78%. This contributed to the annual value of $13.2 million for FY2024, which is 76201.34% up from last year.
  • Per Zenas BioPharma's latest filing, its Shares Outstanding (Weighted Average) stood at $42.2 million for Q3 2025, which was up 44768.78% from $41.9 million recorded in Q2 2025.
  • Zenas BioPharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $42.2 million during Q3 2025, with a 5-year trough of $1.5 million in Q4 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $10.4 million (2024), whereas its average is $18.9 million.
  • The largest annual percentage gain for Zenas BioPharma's Shares Outstanding (Weighted Average) in the last 5 years was 258973.37% (2025), contrasted with its biggest fall of 44768.78% (2025).
  • Zenas BioPharma's Shares Outstanding (Weighted Average) (Quarter) stood at $1.5 million in 2023, then surged by 762.01% to $13.2 million in 2024, then soared by 219.41% to $42.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $42.2 million in Q3 2025, compared to $41.9 million in Q2 2025 and $41.8 million in Q1 2025.